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Abstract
With cannabis medicines now obtaining legal status in many international jurisdictions (generally on the
authorisation of a medical professional), a rapid increase in consumer demand for access to cannabis as a
therapeutic option in the treatment and management of a range of indications is being noted. Despite this
accessibility, knowledge on optimal use is lacking. Further drug development and clinical trials at regulatory
standards are necessary both if a better understanding of the efficacy of cannabis medicines, optimal product
formulation and indication-specific dosing is needed and to ensure the broader quality and safety of cannabis
medicines in the clinical setting.
To enable this, clinical, academic and public calls for the undertaking of rigorous clinical trials to establish an
evidence base for the therapeutic use of cannabis medicines have been made internationally. While this
commitment to undertake human studies with cannabis medicines is welcomed, it has highlighted unique
challenges, notably in the review stages of ethics and governance. This often results in lengthy delays to approval
by Human Research Ethics Committees (herein ‘HREC’, Australia’s nomenclature for Institutional Review Boards) and
trial commencement. A principal concern in these cases is that in contrast to clinical trials using other more
conventional pharmaceutical products, trials of cannabis medicines in humans often involve the use of an
investigational product prior to some (or any) of the preclinical and pharmaceutical safety issues being established.
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This paucity of data around product safety, potential drug interactions, continuity of supply, shelf life and product
storage results in apprehension by HRECs and governance bodies to endorse trials using cannabis medicines.
This manuscript draws from the experiences of Australian researchers and staff involved in clinical trials of cannabis
medicines to describe some of the common difficulties that may be faced in the HREC approval process. It also
presents practical advice aimed to assist researchers, HRECs and governance officers navigate this complex terrain.
While the authors’ experiences are situated within the Australian setting, many of the barriers described are
applicable within the international context and thus, the solutions that have been proposed are typically adaptive
for use within other jurisdictions.
Keywords: Cannabinoids, Human research ethics, Clinical trials, Cannabis medicines, Investigational medicinal
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Introduction
Like many countries, Australia has legalised the use of
cannabis when used as a pharmaceutical-grade product
prescribed by a medical professional for the therapeutic
treatment of management of specific indications [1]. Un-
like the standard pathway followed for other pharma-
ceutical products, a strong and public argument has
been made by consumers and researchers for clinical tri-
als to occur using cannabis medicines as investigational
products in human studies prior to the preclinical and
pharmaceutical safety issues being fully elucidated. Given
this atypical approach, real-world ‘effectiveness’ clinical
trials, including randomised controlled trials, are a
means through which the risks of widespread use of off-
label therapeutics and the collection of rigorous data to
inform clinical practice can be balanced. However,
understandably, this approach often raises seemingly
complex issues for ethics and governance committees
during the review and approval process.
A key concern of HRECs is that many of the studies of
cannabis medicines are undertaken in the outpatient
setting, involving self-medicating. Thus, issues such as
potential use of a concomitant illicit product, adequacy
of storage and dosing, measurement of toxicity, con-
comitant medication use and adequacy of follow-up are
commonly raised. Further, the use of an unregistered
product, such as cannabis medicines, in this relatively
unsupervised setting introduces a novel set of additional
issues for ethics and governance committees to
overcome.
In 2019, a group consisting of Australian lead investi-
gators of large investigator-initiated, Government or
institutionally-funded studies; clinical trials officers; and
regulatory staff came together to discuss common bar-
riers and the lack of clear information available to guide
the process of designing and undertaking clinical trials
using cannabis medicines. Drawing on the current
Australian Research Standards (such as the Australian
National Guidelines, the National Statement on Ethical
Conduct in Human Research) and the authors’ practical
experience navigating these barriers this manuscript of-
fers guidance as to how some of the key issues that arise
when using cannabis medicines as investigational prod-
ucts can be remedied [2].
Through a series of discussions, six (6) common chal-
lenges were identified as the main barriers/issues faced
when submitting clinical trials involving cannabis medi-
cines to Human Research Ethics Committees (HREC)
and regulatory authorities (such as Research Governance
Offices (RGO) in Australia) for review and approval.
These include (1) considerations when selecting canna-
bis medicines products, (2) accurate dosing and adminis-
tration, (3) adverse events, (4) drug-drug interactions, (5)
consent and (6) post-trial access to cannabis medicine
products.
Considerations when selecting cannabis
medicines products in the trial setting
Sourcing a supply of cannabis medicines for use in clin-
ical studies takes time, and the following should be con-
sidered and discussed in the ethics application when
choosing a product for use:
 Does the product meet Good Manufacturing
Practice (GMP) and current Federal and State
regulations (such as the Therapeutic Goods
(Standard for Medicinal Cannabis) (TGO 93) in
Australia [3, 4])?
 Is there a guaranteed consistent supply available for
the duration of the trial?
 Does the supplier of the product have knowledge of,
and experience in the pharmaceutical environment
(e.g. ability to provide an investigator’s brochure)?
Cannabis medicines are available in a variety of prepa-
rations with different concentrations of Cannabidiol
(CBD), Delta-9-tetrahydrocannabinol (THC), other can-
nabinoids, varying terpene combinations, and maybe a
whole plant product or a highly purified extract. Re-
searchers and ethics committees both should be aware
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that one cannabis medicine product, even if available in
the same dose, formulation or concentration, may have
vastly different potency or purity to another. Cannabis
medicine products may also have different absorption
rates and pharmacokinetic profiles due to the variety of
carrier oils, extraction methods and delivery systems
available (such as vaporised, nanotechnology, oral vs.
sublingual). The selection and formulation of the canna-
bis medicines product should, therefore, be clearly de-
fined and explained in the research/study protocol.
Researchers need to be aware that cannabis medicines
used in clinical trials, as with other registered products,
must align with the existing framework for the use of
unregistered/unapproved medications in clinical trials.
This is done by Australia’s federal regulator, the Thera-
peutic Goods Administration (TGA) through their Clin-
ical Trial Notification (CTN) scheme [5]. This scheme
has the required elements to support the documented
use of cannabis medicine products within a clinical trial
in Australia [6]. Additionally, it is recommended that
early consideration should be given to the classification
or scheduling1 of the medicine and other prescribing
regulations around such products, as this will have sig-
nificant impacts on the logistics of a trial. In Australia,
cannabis medicines are currently classified as either a
Schedule 8—Controlled Drug or Schedule 4—Prescrip-
tion Only Medicine, both requiring different national
and state approval schemes for use [8]. For example,
Schedule 8 medicines in the state of New South
Wales, which includes cannabis medicine products
containing THC, also requires State approval. Add-
itional requirements may include specific features
mandated by pharmaceutical regulations, such as the
need for child-resistant openings, instructions for
storage and use, labelling and movement and trans-
portation of the medicine.
Researchers must confirm local requirements and con-
sider the related implications, especially if planning a
multi-site trial across borders. It can be helpful to have a
specific section within the trial protocol which outlines
these elements (referencing the relevant legislation), in-
cluding issues around import/export and product trans-
port, as well as the proposed methods of compliance for
the clinical trial, to provide clarity for members of the
ethics committee.
In the case of outpatient dosing, diversion can be lim-
ited by informing patients that reconciliation of their
returned product will be performed upon return and en-
couraging patients to document drug consumption ac-
curately, including any wastage.
An experienced clinical trial coordinator, collaborative
research group or an accredited clinical trial pharma-
ceutical or contract research organisation can provide
expertise in the import of products, labelling and pack-
aging requirements and assist with meeting all required
regulations. This is particularly important for an unregis-
tered product, particularly when it may also be used with
an unregistered device, such as vaporisers, which may
also require approval from a regulatory body to be used
in a clinical study. Seeking this support is strongly en-
couraged if the necessary skills are not contained within
the supplier or the research team.
Accurate dosing and administration
Cannabis medicines are unique when it comes to dosing
and administration; apart from Nabiximols, there is cur-
rently no registered product information, which trad-
itionally provides dosing schedules for new products.
Dosing is individualised for each patient, with the clini-
cians and patients relying on titration to reach the
optimum dose, if one exists, regardless of the cannabin-
oid content [9, 10]. In Australia, the Federal regulator
recommends that starting doses should be low and in-
creased over time until patients respond positively, or
the negative effects outweigh the perceived benefits [11].
Product information dosing guidance has been devel-
oped in the interim to help ethics committees with this
issue [9, 12]. Investigators can utilise a broad range of
published data to outline the parameters they have used
to inform the dosing schedule, which may include data
in other populations, or from other cannabis medicines
studies. To support informed ethical review, clarity
around these data and decisions that have been made is
an important part of the study rationale.
Additional factors that may affect dosing include
the underlying condition being investigated, the type
of product used, route of administration, dosage regi-
men, individual patient variation, possible develop-
ment of tolerance, interaction with other medications
and previous exposure to cannabis, either recreation-
ally or medically [9].
As with all drugs, lower doses are less likely to be as-
sociated with adverse effects, possibly limiting thera-
peutic doses being achievable without toxicity, such as
sedation without pain relief. To determine the efficacy of
the cannabis medicine product for the patient and their
medical condition, clinicians and patients need to work
together to determine a personalised dosage escalation
regimen, including starting dose and develop a plan for
dose increments or decrements where the patient benefit
is maximised, and adverse effects are minimised.
1Under the Australian regulatory system overseen by the Therapeutics
Goods Administration (TGA), medicines and poisons are scheduled
according to the level of regulatory oversight required to protect
public health and safety [7]. Therapeutic Goods Administration.
Scheduling of medicines & poisons [Internet] 2016 [cited 07 August
2020]. Available from: https://www.tga.gov.au/scheduling-medicines-
poisons
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When selecting a cannabis medicine product for a
clinical trial, the mode of administration is important,
depending on whether a large exposure is needed, for
example with chronic pain, where constant concentra-
tions above a minimum are needed, or if a high max-
imum concentration is needed for a short time, e.g. for
breakthrough pain. Rapid onset can be achieved by
choosing an administration method bypassing metabol-
ism in the liver, i.e. not oral. Examples include the com-
monly used inhaled (vaporised) route and oral mucosal,
but developing routes for rapid absorption include
transdermal, intranasal, buccal and sublingual routes.
Researchers may also need to consider complexities such
as using specific volumes and concentrations for doses
and include and actual dose amount, such as milligram
per day measured. Storage and administration devices
such as droppers, vaporisers and non-pharmaceutical
standard storage bottles must be checked for residual
medicine and include specifications on the cleaning of
delivery devices. Many of the above issues can poten-
tially be eliminated by choosing a simpler, standardised
route and a pharmaceutical-grade product and dispen-
ser. One such option is encapsulating the medicine using
preloaded vaporised dosing [13].
Adverse events
Two elements of safety need to be considered in canna-
bis medicines trials; this is no different to the Inter-
national Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use
(ICH) Good Clinical Practice (GCP) E6 (R2) require-
ments for clinical trials of other interventions. Firstly,
the safety data which underpins the study design ele-
ments, such as participant population, dosing and
expected adverse effects [14]. The second is to outline a
safety monitoring approach, which is based on available
data considering the population under study. The inter-
pretation of safety data for cannabis medicines is
complicated. While cannabis has been used by humans
for millennia, details of the short- and long-term adverse
reactions profile remains poorly understood. Overall, the
known common adverse effects of cannabis medicines
include sedation/somnolence, dizziness, anxiety, cogni-
tive dysfunction, nausea, vomiting, diarrhoea, vertigo, in-
creased or decreased appetite and dry mouth [15]. The
adverse event profile of different formulations varies de-
pending on the ratio of CBD: THC, the presence and
amount of other cannabinoids and terpenes and the dose
prescribed [16]. THC, particularly at higher doses, may
be associated with treatment-emergent hallucinations,
perceptual disturbances or paranoia [17].
ICH-GCP provides specific guidance on the proce-
dures for assessing, classifying, documenting and report-
ing adverse events [2]. There is a lack of a standardised
measure for assessing adverse events of cannabis medi-
cines so all adverse events should be recorded and
reported. Researchers may choose to use a measure such
as the Common Terminology Criteria for Adverse Events
version 5 for describing adverse events [18, 19].
Blood tests may be conducted to assess for treatment-
emergent abnormalities in haematology, biochemistry
and liver functioning. Antiepileptic blood concentrations
and concentrations of other drugs metabolised by the
cytochrome P450 (CYP450) enzyme system may require
monitoring depending on the study [20, 21].
In addition to routine biochemical and haematological
monitoring, any unusual event, including large changes
in heart rates and blood pressure, should be recorded
both during the trial and for a specified duration after
the trial has concluded. Furthermore, it should be noted
that safety data from plant-derived cannabis products
cannot be applied to synthetic cannabinoids, the safety
of which needs to be considered independently.
Drug-drug interactions
Currently, cannabis medicines used in clinical trials
utilise either a single cannabinoid extract (THC or CBD)
or a combination of these two cannabinoids in varying
ratios, and as part of a whole plant product or as com-
bined extracts, with or without added minor cannabi-
noids or terpene extracts. The pharmacokinetics and
pharmacodynamics of most analogue cannabinoids are
not known and little work has been undertaken on the
stereoisomeric forms of the cannabinoids or pharmaco-
genomic studies on their metabolism [22].
THC and CBD are metabolised by the CYPP450
system. The CYP system is also a common site for drug-
drug interactions, which have been responsible for many
deaths in Australia [23]. Inhibition by drugs such as
ketoconazole and clarithromycin significantly increase
concentrations of THC and CBD, while inducers such as
rifampicin, carbamazepine and St John’s Wort lower
THC and CBD concentrations. Other, pharmacody-
namic (PD) interactions may occur at the level of the
endocannabinoid receptor but are not yet known, in-
cluding G-protein-coupled receptors (GPCR) interac-
tions and common binding of cannabinoids to mu,
dopamine, serotonin and similar receptors [24].
As per standard clinical trial practice, complete details
of any co-administered medications, alcohol intake, to-
bacco smoking and complementary medications should
be recorded, and dosing of a cannabis medicine product
altered as medication changes. Adherence to GCP guide-
lines requires that the mode of delivery, duration of
cannabis medicines therapy and previous exposure to
cannabis are documented in the evaluation of any thera-
peutic effect. Similarly, this information needs to be
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reported in accordance with good pharmacovigilance
practice in the recording of adverse drug reactions.
Consent
There has been a strong consumer demand for cannabis
medicines [25], particularly in the setting of life-limiting
conditions and symptom control. The population is gen-
erally comprised of vulnerable people, such as children
with epilepsy, patients moving towards the palliative care
phase of their illness and people living with mental
health issues, or drug and alcohol dependence [26].
Often, these vulnerable populations are willing to ‘try
anything’ to alleviate difficult to manage symptoms.
In line with the Australian National Guidelines, par-
ticipation in cannabis medicines trials, as with any clin-
ical trial, must be voluntary and based upon enough
information, and with the ability to withdraw consent
and involvement in research at any time without preju-
dice [2, 27]. An individual’s capacity to consent must be
assessed, and it is important to note that a participant’s
capacity may fluctuate with time and situation during
trials using cannabis medicines due to sedative effects
[28]. While it is not a requirement in Australia that con-
sent is routinely witnessed [2], we recommend that
participant consent should be witnessed in cannabis
medicines trials to ensure participant safety and self-de-
termination. Participants must also be advised that
they will be unable to drive or operate heavy machin-
ery while taking a cannabis medicine product contain-
ing THC.
Post-trial access
Post-trial access is an ethical obligation should the study
drug prove safe and effective and must be considered
during the development of the protocol. Researchers
should confirm ongoing access pathways and communi-
cate this to participants at the time of consent [29]. Con-
sideration should also be given to the most appropriate
alternative cannabis medicine product in the event of
supply issues. Due to the botanical nature of the source
of the study drug and variation in base excipients be-
tween manufacturers, it may be difficult to identify an
alternate product to the specific medication used in a re-
searcher’s clinical trial.
To ensure ongoing clinical care and safety monitoring
of a participant, open-label extension of a clinical trial is
common, with the treatment provided at no cost and
the benefit of continued data collection in a managed ac-
cess programme [30]. The CARE NSW trial in Australia
is an example of such a trial to adopt this mechanism in
the advanced cancer population; however, this is uncom-
mon due to cost, sponsor unwillingness and logistical is-
sues, such as coordination of access by research staff,
who may be employed only for the period of the trial.
Open-label extensions are not an ethical requirement;
however, patients must be informed that medication
supply will not be available at the end of the study [31].
The alternative that can be included in a study proto-
col is to utilise the existing framework for prescribing
non-registered medicines. In Australia, approved canna-
bis medicine products which meet TGO93 may be pre-
scribed post-trial at the direct cost of the patient
through Australia’s TGA special access schemes (SAS)
or by their doctor obtaining personal authority to be a
registered prescriber of cannabis medicines [32]. It is,
however, important to highlight the cost burden of this
to participants in advance.
Availability of and access to cannabis medicines for
participants post-trial must, therefore, be confirmed dur-
ing protocol development, and arrangements should be
clearly communicated in the Protocol and Patient Infor-
mation Sheet and Consent Form (PICF).
Conclusion
Notwithstanding the need to adhere to the National,
Federal and State guidelines, recently clinicians, public
health professionals and academics are concerned about
the barriers arising through the ethics review process,
often due to the complexity for committees of navigating
large clinical trials using (often unregistered) cannabis
medicines. While cannabis medicines are a relatively
new and promising therapy, clinical trials need to be
undertaken to understand how to demonstrate their effi-
cacy and safety in different conditions. Thus, it is likely
that ethics and governance committees will receive an
increasing number of research protocols involving stud-
ies of cannabis medicines for review. However, because
cannabis is also an illicit substance when used outside of
regulated medical settings, it is imperative to educate
staff working in the ethics and governance about the
major differences between illicit cannabis and cannabis
medicines. Education and discussion for all key stake-
holders to address the current perceived risks, including
product safety, regulations, storage and supply will ease
concerns from ethics committees around such trials.
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